Jazz Pharmaceuticals (NASDAQ:JAZZ) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
This table compares Jazz Pharmaceuticals and Dicerna Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Jazz Pharmaceuticals and Dicerna Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jazz Pharmaceuticals presently has a consensus target price of $192.28, suggesting a potential upside of 21.07%. Dicerna Pharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 43.61%. Given Dicerna Pharmaceuticals’ higher probable upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than Jazz Pharmaceuticals.
Institutional and Insider Ownership
92.5% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 74.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 3.9% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 19.9% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Jazz Pharmaceuticals and Dicerna Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals||$1.62 billion||5.93||$487.84 million||$9.56||16.61|
|Dicerna Pharmaceuticals||$2.28 million||358.66||-$60.04 million||($3.66)||-3.61|
Jazz Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Jazz Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.
Jazz Pharmaceuticals beats Dicerna Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.